Back to all assets

AbbVie ABBV

equity

Price History

$36.69$108.34$179.99$251.64
2013-01 · DCA start$36.69

Time underwater

How far below its previous all-time high the price sat, each month. 0% means a new high.

-43.2%-28.8%-14.4%0.0%
2013-012026-08 · -1.1%

Worst drawdown: −43%, peaking Feb 2018 and bottoming Aug 2019 — 41 months below the prior high before recovering.

DCA Backtest

Invested
$16,400
Value today
$47,055
Return
+186.9%
Months invested
164

Scenarios

Inflation — the same contributions merely keeping pace with CPI would be $20,544 today, so the real (inflation-adjusted) return is +129.0%.

Lump sum instead — $16,400 all at once in Jan 2013: $111,193 (+578.0%) — lump sum came out ahead.

Worst timing — same monthly amount started at the all-time high (Jun 2026): $297.99 on $300 invested (-0.7%).

⚠ Price returns only — dividends are not included. This understates the true return of dividend-paying shares, and any comparison against crypto (which pays no dividends) is biased against equities by roughly the dividend yield, compounded.

If this saved you a spreadsheet — buy me a coffee.

Every start month at once

Each cell is the return-to-date of £/$/€100-a-month DCA started that month. Click a cell to load it in the backtest above. The ringed cell is the all-time-high start — the worst timing scenario.

JFMAMJJASOND
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Legend:−50%−20%0%+50%+200%+1000%worst timing (ATH)Selected 2013-01: +186.9%

About AbbVie

AbbVie Inc., also known as AbbVie, is an American pharmaceutical company headquartered in North Chicago, Illinois. AbbVie produces drugs to treat a wide range of medical issues. (Wikipedia)

It's a listed company categorised under health care and biotechnology, with a market cap of about $439.6B.

It rates Medium-Low Risk at 2.0/5, meaning the rated factors are mostly sound, with one or two areas worth watching.

What pushes the score up: leverage / financial (3.0/5) and sector / regulatory (3.0/5).

Scoring well: earnings quality at 1.0/5.

Not yet researched: concentration, governance. These are excluded from the score rather than guessed, so the real risk may be higher than what’s shown.

Ratings summarise sourced facts against fixed rules — not investment advice, and no substitute for your own diligence.

Risk Profile

Medium-Low Risk(2.0/5)80% rated

How these ratings work

Market / Volatility2.0/5 · weight 20%
  • Annualised volatility (3yr)2/521.3
  • Max drawdown from ATH2/543.2
  • Beta vs S&P 5002/50.65
Liquidity1.0/5 · weight 15%
  • Avg daily $ volume1/51.6bn
  • Float % of shares outstandingnot yet researched
Leverage / Financial3.0/5 · weight 20%
  • Debt / equitynot yet researched
  • Interest coverage (EBIT / interest)3/55.2
Earnings Quality1.0/5 · weight 15%
  • 3yr EPS volatility1/57.7
Concentrationunrated · weight 10%
  • Largest customer, % of revenuenot yet researched
  • Geographic revenue concentrationnot yet researched
Governanceunrated · weight 10%
  • Board independence %not yet researched
  • Share structurenot yet researched
  • Litigation / audit historynot yet researched
Sector / Regulatory3.0/5 · weight 10%
  • Sector regulatory exposure3/5elevated

Linked Assets

Same sector, or return-correlated — worth knowing what else might move if this one does.